Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors added to regular statin therapy on target lesion failure (TLF) and arteriosclerosis progression in patients with chronic total occlusions (CTOs) undergoing successful percutaneous coronary intervention (PCI).

Clinical Trial Description

Chronic total occlusions (CTOs) are found in 15-25% of patients with stable angina pectoris. The presence of a CTO indicates unfavorable prognosis, with higher rate of major adverse cardiovascular events. Statins are frequently used after PCI in order to lower LDL cholesterol levels and reduce the chances of coronary artery obstruction recurring. Despite this preventive measure, high risk for restenosis and re-occlusion was observed a significant proportion of patients with CTOs undergoing PCI. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors represent a novel class of lipid-lowering drugs leading to rapid, profound, and consistent reductions in LDL-C levels. The effect of PCSK9 inhibitor in patients with CTO, after a recent PCI is not known. In this study the investigators want to evaluate the effect of the PCSK9 inhibitor on neointimal hyperplasia and target lesion failure (TLF) in patients with CTOs receiving regular statin treatment. A serial of intravascular ultrasound imaging study will be performed to determine the arteriosclerosis progression at 48 weeks. ;

Study Design

Related Conditions & MeSH terms

In-stent Restenosis
Major Adverse Cardiovascular Events

Clinical Trial Details

NCT number	NCT05623995
Study type	Interventional
Source	Beijing Anzhen Hospital
Contact	Xu Wang, MD
Phone	+8615311765609
Email	huaianwangxu@126.com
Status	Recruiting
Phase	Phase 4
Start date	December 15, 2022
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00341562` - Genomics of In-Stent Restenosis	N/A
Completed	`NCT05509296` - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease	N/A
Not yet recruiting	`NCT06090890` - Anti-inflammatory Therapy for Recurrent In-stent Restenosis	Phase 4
Active, not recruiting	`NCT00998439` - Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter	Phase 2
Active, not recruiting	`NCT05731700` - CVT-ISR First in Human Trial for Coronary In-Stent Restenosis	N/A
Completed	`NCT03260517` - The PREVAIL Study	N/A
Not yet recruiting	`NCT03588962` - Metal Allergy In-Stent Restenosis Study	N/A
Completed	`NCT00393315` - P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses	Phase 2
Recruiting	`NCT03874481` - The Effect of Sleep Quality on Coronary Artery Disease and In Stent Restenosis
Active, not recruiting	`NCT01127958` - DARE-trial: A Trial Studying the Effect of the SeQuent Please Drug-eluting Balloon Compared to the Xience Prime Drug-eluting Stent for the Treatment of Stenosis of an Earlier Implanted Stent.	N/A
Active, not recruiting	`NCT04647253` - A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)	Phase 3
Active, not recruiting	`NCT03529006` - Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis	N/A
Completed	`NCT00485030` - Diffuse Type In-Stent Restenosis After Drug-Eluting Stent	Phase 4
Not yet recruiting	`NCT03809754` - Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis	N/A
Completed	`NCT00916279` - PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis	Phase 1/Phase 2
Recruiting	`NCT05473884` - Lesion Preparation in Femoropopliteal Artery Occlusion Disease
Recruiting	`NCT01239940` - RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)	Phase 4
Active, not recruiting	`NCT01239953` - RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)	Phase 4
Not yet recruiting	`NCT06148441` - Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention
Completed	`NCT05512832` - In-stent Restenosis and Pericoronary Fat Attenuation Index